GENE ONLINE|News &
Opinion
Blog

2020-09-18| Asia-Pacific

Eisai Enters Vietnam With a Subsidiary

by Sahana Shankar
Share To

Japanese pharma Eisai Co., Ltd announced a pharmaceutical sales subsidiary in Ho Chi Minh, Vietnam on September 14, 2020. With Vietnam emerging as a sizeable market within South East Asia, the pharmaceutical market clocked in +10.6% compound annual growth from 2014 to 2019.

By Sahana Shankar, Ph.D. Candidate

The expected growth rate is estimated to continue in double digits for the coming years, owing to the expansion of middle-income groups and an increase in non-communicable diseases.

Eisai (Thailand) Marketing Co., Ltd operated in Vietnam through a local agency since 1992. In 1995, Eisai established a representative office in Ho Chi Minh City, with proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy drug Mathylcobal, among others.

With Eisai Vietnam, Eisai targets enhanced sales in Vietnam and the delivery of innovative drugs to patients. Eisai launched a new anti-epileptic drug Fycompa in 2019 and has anti-cancer agents, Lenvima and Halaven at different regulatory processes levels.

Eisai Co., Ltd is a pharmaceutical company headquartered in Tokyo, Japan, with a global network of 10,000 employees, R&D facilities, manufacturing, and marketing subsidiaries focusing on neurology and oncology products.

Related Article: Eisai Obtains Novel Anti-Cancer Molecules via PRISM BioLab Contract

Reference:

https://www.eisai.com/news/2020/news202055.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Neurolief’s Neuromodulation Device Receives Japanese Approval for At-Home Migraine Treatment
2024-01-16
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
Revolutionary Wristband Sensor Technology Predicts Alzheimer’s Risk
2024-01-04
LATEST
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
EVENT
Scroll to Top